ABAMUNE-L – Composition, Uses and Medicine Enquiries
Product Overview
ABAMUNE-L is a product listed under the antiretroviral category as a combination of two nucleoside reverse transcriptase inhibitors. Its active composition is Abacavir 600 mg + Lamivudine 300 mg. It is associated with HIV-1 infection as part of a complete combination regimen.
The product combines two reverse-transcriptase inhibitors that reduce viral replication. Suitability depends on the diagnosis, approved labeling, clinical history and specialist assessment.
This information is provided for education and product identification, not as a recommendation to begin treatment. HLA-B*5701 screening is important. Hepatitis B coinfection, renal function and drug interactions should also be evaluated. A qualified clinician should confirm whether this exact brand, strength and formulation are appropriate before any prescription or treatment decision.
Composition and Strength
| Product Detail | Information |
|---|---|
| Product Name | ABAMUNE-L |
| Generic Name | Abacavir + Lamivudine |
| Brand Name | ABAMUNE-L |
| Strength | Abacavir 600 mg + Lamivudine 300 mg |
Therapeutic Category and Indication
Therapeutic Category: Antiviral / Antiretroviral
Medicine Class: Dual nucleoside reverse transcriptase inhibitors
Associated Indication: HIV-1 infection as part of a complete combination regimen
The principal clinical use associated with ABAMUNE-L is HIV-1 infection as part of a complete combination regimen. In general, its active ingredients combine two reverse-transcriptase inhibitors that reduce viral replication.
Treatment eligibility may depend on diagnostic tests, organ function, other medicines and the relevant national prescribing information. The original spreadsheet category or indication may not accurately represent the brand-specific approval. A qualified pharmacist should check the approved product label before publication.
HLA-B*5701 screening is important. Hepatitis B coinfection, renal function and drug interactions should also be evaluated.
Administration Information
The supplied product information states that ABAMUNE-L is taken orally as directed within a complete antiretroviral regimen.
Follow the exact prescribed route, dose and schedule. Do not change, share or discontinue this medicine without the treating professional’s advice. Review the manufacturer’s patient instructions.
Product Presentation and Availability
- Product: ABAMUNE-L
- Active Composition: Abacavir 600 mg + Lamivudine 300 mg
- Manufacturer/Marketer listed in the spreadsheet: Cipla Ltd
- Pack Size: Requires verification
- Dosage Form and Current Labeling: Confirm from the actual manufacturer pack
The manufacturer/marketer attribution, current pack size, dosage form, labeling, batch details and expiry must be independently verified. No particular packaging, stock or delivery is promised by Medinglobal.
Prescription and Patient Safety
The supplied product information highlights the importance of HLA-B*5701 screening before treatment. Hepatitis B coinfection, renal function and drug interactions should also be evaluated.
A qualified clinician must assess whether the exact product and formulation are appropriate. Do not start, change or discontinue treatment without the treating professional’s advice.
This information is for education and product identification only. It is not a recommendation to begin treatment.
Medicine Enquiry Coordination Through Medinglobal
Medinglobal receives enquiries about ABAMUNE-L and may coordinate requests for product information with independent, appropriately authorized pharmaceutical providers.
Medinglobal is not the manufacturer, direct seller, dispensing pharmacy or exporter of this product. Any permitted transaction, prescription check, destination-country assessment, supply terms and supporting documentation are handled by the relevant authorized provider.
An enquiry does not guarantee availability or supply.
How to Submit an ABAMUNE-L Enquiry
To submit an enquiry, provide:
- Product name: ABAMUNE-L
- Strength: Abacavir 600 mg + Lamivudine 300 mg
- Required formulation
- Required quantity
- Destination country
Include a valid prescription or institutional documents when required. Medinglobal may connect the enquiry with an appropriately authorized independent provider, which must independently confirm legality, product identity and any applicable commercial terms.
Frequently Asked Questions
What is ABAMUNE-L used for?
It is associated with HIV-1 infection as part of a complete combination regimen, subject to the exact approved label and medical assessment.
What does ABAMUNE-L contain?
It contains Abacavir 600 mg + Lamivudine 300 mg. Confirm the final composition on the manufacturer pack.
How is ABAMUNE-L administered?
The supplied information states that it is taken orally as directed within a complete antiretroviral regimen.
Can I request product information through Medinglobal?
Yes. Medinglobal can receive a coordination enquiry. Supply is neither guaranteed nor directly undertaken by Medinglobal.



Reviews
There are no reviews yet.